Eplerenona Pentafarma Indications/Uses

EPLERENONA PENTAFARMA TABLETS (eplerenone) is indicated as an adjunct to standard therapy to reduce the risk of cardiovascular mortality and hospitalization for heart failure in patients with NYHA class II systolic chronic heart failure and left ventricular systolic dysfunction. In patients 75 years and older a reduction in cardiovascular mortality was not observed with EPLERENONA PENTAFARMA TABLETS (see Use in the Elderly under Precautions).
EPLERENONA PENTAFARMA TABLETS (eplerenone) is indicated as an adjunct to standard therapy to reduce the risk of mortality and hospitalization for heart failure following myocardial infarction in clinically stable adult patients who have evidence of heart failure and left ventricular systolic dysfunction (ejection fraction ≤40%). In patients 75 years and older a reduction in mortality was not observed with EPLERENONA PENTAFARMA TABLETS (see Use in the Elderly under Precautions).
Serum potassium level should be measured and glomerular filtration rate should be estimated before starting EPLERENONA PENTAFARMA TABLETS therapy and EPLERENONA PENTAFARMA TABLETS should not be administered if initial serum potassium is >5.0 mmol/L or if estimated glomerular filtration rate is <30 mL/min/1.73 m² (see Contraindications, Precautions, and Dosage & Administration).